Investigational Drug Information for LY3372689
✉ Email this page to a colleague
What is the drug development status for LY3372689?
LY3372689 is an investigational drug.
There have been 6 clinical trials for LY3372689.
The most recent clinical trial was a Phase 1 trial, which was initiated on September 16th 2021.
The most common disease conditions in clinical trials are Alzheimer Disease and [disabled in preview]. The leading clinical trial sponsors are Eli Lilly and Company and [disabled in preview].
There are two US patents protecting this investigational drug.
Summary for LY3372689
| US Patents | 2 |
| International Patents | 0 |
| US Patent Applications | 6 |
| WIPO Patent Applications | 5 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 1 (2021-09-16) |
| Vendors | 15 |
Recent Clinical Trials for LY3372689
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Carbon-14-Labelled [14C] LY3372689 in Healthy Male Participants | Eli Lilly and Company | Phase 1 |
| A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease | Eli Lilly and Company | Phase 2 |
| A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants | Eli Lilly and Company | Phase 1 |
Clinical Trial Summary for LY3372689
Top disease conditions for LY3372689
Top clinical trial sponsors for LY3372689
US Patents for LY3372689
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| LY3372689 | ⤷ Start Trial | 5-methyl-1,2,4-oxadiazol-3-yl compounds | Eli Lilly and Co | ⤷ Start Trial |
| LY3372689 | ⤷ Start Trial | Combination therapy | Eli Lilly and Co | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
